

# **Satin Creditcare Network**

## Results in line; focus on process re-engineering

Satin results were as per expectations. AuM growth was in-line though NII growth came in lower owing to margin compression basis the assignment income booked in other income. PPoP at Rs800mn was largely as expected. The company's focus remains on 1) process evolution by relying on digital initiatives and 2) achieving a pan India presence. This may lead to a more calibrated asset growth although portfolio quality is set to improve as credit checks have become tighter. The impact of the flood related stressed portfolio may not be significant though we have taken a more conservative stance on credit costs. We see the high RoA / RoE trajectory to be maintained at 3.1% / 18.9% in FY21E. Valuation at 1.0x is attractive. We retain our Buy rating though revise TP to Rs410 (vs Rs420 earlier).

#### Q1FY20 results as expected

AUM / disbursements grew 20% / 35.5% YoY led by customer acquisition (+25% YoY). Assignment rose from Rs80mn to Rs1.48bn YoY. NII saw a 20% YoY decline as reported NIM compressed by 46bps YoY to 11.4% given a sharp yield decline. NIM reduction was also due to assignment income of Rs389mn being included in other income. Cost to income (C/I) improved QoQ by ~31bps to 56.4%. PPOP came in-line at Rs796mn (+7.8% YoY). Asset quality was stable with GNPA / ECL at 2.8% / 1.6% QoQ. PAT came in at Rs414mn (est. of Rs447mn). CAR remains strong at 30.5% (CET – 1 at 23%).

#### AuM growth to be more controlled as focus is on streamlining processes

Management has been focusing on process re-engineering by continuously investing in technology. Cashless disbursements / collections have gone up to 100% / 12% and the target is to scale up cashless collections to 50% by FY20E. Having a pan India presence is a priority and hence expansion may be in states with a low presence. The target is to cap its per state exposure to < 20% by FY20E. UP currently contributes ~22% to GLP (vs 22% in Q4FY19). Focus on processes may lead to a more controlled AuM growth and elevated opex. Over FY19-21E we see an AuM CAGR of 25.6% while cost to income is expected remain at 52%. MFI contribution is guided to be 2/3<sup>rd</sup> within 4-5 years.

## Target to improve portfolio quality; we are a bit cautious on credit costs

The company has shifted to a centralised service centre versus a back-ended one to have a greater control on processes. Also, running psychometric tests has led to better selection of customers across geographies. This has led to tightened credit checks and rise in rejection rates from 12% to 18% and as per an internal study 57% of the time, Satin is the only lender, suggesting improved credit processes and the untapped MFI potential. Collection efficiency is consistent at 99.4% for loans disbursed since Jan'18. Also, the flood related stressed portfolio may not have a significant impact though there are some signs of stress in the Eastern India portfolio. We are cautiously baking in provision costs of 120bps each for FY20 and FY21.

#### Valuation and risks

We have lowered our AUM growth estimates for FY20/FY21E though fundamentally we like Satin basis its business model and return ratios. Resultantly we see a slight correction in FY21 ABVPS. We maintain our multiple of 1.5x FY21 ABV and revise TP to Rs410 (vs Rs420 earlier). Risks to our call include higher opex and spike in NPA.

## **Financial and valuation summary**

Source: Company, Centrum Research estimates

YE Mar (Rs mn)	Q1FY20	Q1FY19	YoY (%)	Q4FY19	QoQ (%)	FY19	FY20E	FY21E
NII	1,209	1,512	(20.0)	1,065	13.5	5,405	6,631	8,336
PPoP	796	738	7.8	726	9.6	3,577	4,157	5,207
Provisions	146	358	(59.3)	(121)	NA	521	774	973
PAT	414	250	65.2	555	(25.4)	1,949	2,165	2,710
AUM growth (%)	19.8	43.2	(23.5)ppt	25.4	(5.6)ppt	25.3	24.7	26.4
NIM (%)	11.4	11.8	(46)bps	12.0	(62)bps	8.1	7.9	8.0
C / I (%)	56.4	49.1	723bps	59.5	(309)bps	51.3	52.2	51.9
GNPA (%)	2.8	3.9	(113)bps	2.9	(10)bps	2.8	3.1	3.3
RoA (%)	2.5	1.5	94bps	3.3	(84)bps	3.0	3.0	3.1
RoE (%)	13.5	10.7	277bps	20.0	(647)bps	19.1	18.0	18.9

#### **Result Update**

## India I Diversified Financials

9 August 2019

## Buy

Target Price: Rs410 Price: Rs275 Forecast return: 49%


#### Market Data

Bloomberg:	SATIN IN
52 week H/L:	Rs410/183
Market cap:	Rs13bn
Shares outstanding:	48mn
Free float:	49.8%
Avg. daily vol. 3mth:	36760
Source: Bloomberg	

#### Changes in the report

Rating:	Unchanged
Target Price:	To Rs410 from Rs420
Earnings est.:	(5.3)% FY20E, (7.8)% FY21E
Source: Centrum Resear	ch

## **SATIN** relative to Nifty Midcap 100



#### Shareholding pattern

	Jun-19	Mar-19	Dec-18	Sep-18
Promoter	29.7	27.9	26.7	26.7
FIIs	13.3	14.8	14.9	14.5
DIIs	23.9	21.7	20.6	17.4
Public/oth	33.1	35.6	37.8	41.4
Source: BSE				



Analyst, Banks, Diversified Financials +91 4215 9110 gaurav.jani@centrum.co.in



Cyrus Dadabhoy Analyst, Banks, Diversified Financials +91 4215 9980 cyrus.dadabhoy@centrum.co.in



Rahul Nandwani Associate, Banks, Diversified Financials +91 22 4215 9364 rahul.nandwani@centrum.co.in

# **Thesis Snapshot**

## **Estimate revisions**

YE Mar (Rs mn)	FY20E New	FY20E Old	% chg	FY21E New	FY21E Old	% chg
NII	8,694	9,423	(7.7)	10,825	11,890	(9.0)
PPoP	4,157	4,381	(5.1)	5,207	5,532	(5.9)
PAT	2,165	2,287	(5.3)	2,710	2,938	(7.8)
AUM growth (%)	24.7	30.3	(561)bps	26.4	27.8	(138)bps
GNPA	3.1	2.5	61bps	3.3	2.8	52bps

Source: Centrum Research estimates

## **Centrum estimates vs Actual results**

YE Mar (Rs mn)	Centrum Q1FY20	Actual Q1FY20	Variance (%)
NII	1,390	1,209	(13.0)
PPoP	819	796	(2.8)
PAT	447	414	(7.4)
AuM growth	18.7	19.8	106bps

Source: Bloomberg, Centrum Research estimates

## Satin versus Nifty Midcap 100

	1m	6m	1 year
SATIN IN	(0.3)	16.8	(30.0)
Nifty Midcap 100	(6.8)	(3.9)	(17.1)

Source: Bloomberg, NSE

## **Key assumptions**

YE Mar (Rs mn)	FY20E	FY21E
AUM growth (%)	24.7	26.4
NIM (%)	7.9	8.0
Other inc / Assets (%)	0.9	0.9
Cost / Assets (%)	6.2	6.4
Provision costs	1.2	1.2

Source: Centrum Research estimates

## **Valuations**

We have lowered our AUM growth estimates for FY20/FY21E though fundamentally we like Satin basis its business model and return ratios. Resultantly we see a slight correction in FY21 ABVPS. We maintain our multiple of 1.5x FY21 ABV and revise TP to Rs410 (vs Rs420 earlier). Risks to our call include higher opex and spike in NPAs.

Valuations					
FY21E ABVPS (Rs)	284				
Historical P / ABV (x)	2.1				
Premium assigned (%)	(28.6)				
Ascribed P / ABV (x)	1.5				
Fair value / share (Rs)	410				



## Sensitivity analysis

		AuM						
		+ 10bps	+ 20bps	' Current levels	- 10bps	- 20bps		
	- 5bps	(2.7)	(3.5)	(1.9)	(1.2)	(0.4)		
_	- 10bps	(4.6)	(5.4)	(3.9)	(3.1)	(2.3)		
Σ	<b>Current levels</b>	(0.8)	(1.6)	-	0.8	1.6		
_	+ 5bps	1.2	0.4	1.9	2.7	3.5		
	+ 10bps	3.1	2.3	3.9	4.6	4.6		

Source: Bloomberg, Centrum Research estimates

## Peer comparison

Company Mkt Cap Rs bn	Mkt Cap	CAGR FY19-FY21E (%)		P/BVPS		RoA (%)			RoE (%)				
	Total inc	PPOP	PAT	FY19	FY20E	FY21E	FY19	FY20E	FY21E	FY19	FY20E	FY21E	
Satin	12.8	21.4	20.7	17.9	1.3	1.2	0.9	3.0	3.0	3.1	19.1	18.0	18.9
Ujjivan	33.8	33.6	64.2	34.9	2.0	1.8	1.2	1.7	1.5	1.7	10.7	12.1	13.3
Equitas	36.2	26.9	42.8	44.9	1.8	1.3	1.1	1.2	1.7	1.9	7.5	12.5	15.4

Source: Company, Centrum Research estimates

Fig 1: Key concall takeaways and metrics

FY20E Guidance	Q1FY20	Q4FY19	Our Comments
AuM growth	30%+	30-35%	Although the company has guided for 30%+ AuM growth, given the focus of the company on process re-engineering and resultant controlled growth we are conservatively factoring in a CAGR of 25.6% over FY19-21E.
NIM	Stable	Stable	Due to its loan and customer profile basis its micro lending business model, and its maturity pattern of loan and borrowings, passing on the cost of funds movement to customers may not be a challenge. Management expects NIM to be stable in the near term and we have factored the same into our estimates.
Орех	Opex efficiency to improve	Opex efficiency to improve	The company has been investing in technology to streamline its processes and it has guided to substantially expand its branch network in the near term due to focus on diversifying its state concentration. Hence we expect opex in terms of cost to income to remain elevated in the near term. See cost to income at 52% in FY20E and FY21E
Provisions costs	<100bps	< 100bps	Conservatively we are factoring in provisions of 120bps each for FY20 and FY21 due to the impact of floods in certain parts of India, anecdotal evidence of overheating and rural stress.
Consol. PAT	Rs.260crs	Rs.260crs	Consol. PAT of Rs.2.6bn is guided for FY20. We see a standalone PAT of Rs2.2bn for FY20 as we have been cautious on our estimates in terms of AuM growth, opex and provision costs.

Source: Company, Centrum Research estimates

Fig 2: Quarterly Financials

Tig 2. Quarterly i maricials								
Profit & Loss (Rs mn)	Q2FY18	Q3FY18	Q4FY18	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20
Interest earned	2,324	2,413	2,713	3,045	3,152	3,022	2,575	2,715
Interest expended	1,271	1,324	1,440	1,533	1,681	1,666	1,510	1,506
Net interest income	1,053	1,089	1,273	1,512	1,472	1,356	1,065	1,209
Other income	27	43	64	51	316	792	726	614
Total income	1,081	1,132	1,337	1,563	1,788	2,148	1,791	1,824
Operating expenses	645	747	714	825	914	909	1,065	1,028
Employees	466	513	474	597	617	703	731	730
Others	180	234	240	228	298	206	333	298
Operating profit	435	385	623	738	874	1,239	726	796
Provisions	(711)	(374)	(2)	358	184	99	(121)	146
Profit before tax	1,146	759	625	380	690	1,139	847	650
Tax	402	271	213	129	246	439	292	236
Profit after tax	744	488	411	251	444	700	555	414
Balance sheet								
AUM (Rs mn)	39,875	43,044	50,848	54,002	55,612	55,900	63,740	64,670
AUM growth (%)	5.8	7.9	18.1	6.2	3.0	0.5	14.0	19.8
Total CRAR (%)	20.9	26.6	23.7	26.4	25.2	30.1	28.5	30.5
Profitability ratios (reported %)								
Gross yield	24.7	24.0	23.5	23.5	25.3	23.7	22.1	20.7
Financial cost	12.3	11.9	10.3	11.7	12.3	12.8	10.1	9.4
NIM	12.4	12.1	13.2	11.8	13.1	10.9	12.0	11.4
Opex ratio	6.6	6.9	6.3	6.2	6.7	7.2	7.1	6.4
Loan loss ratio	3.8	1.7	1.3	2.8	1.3	(3.6)	(0.8)	0.9
ROA	1.1	1.8	3.3	1.5	2.6	3.8	3.3	2.5
Leverage	5.4	4.0	4.1	6.0	5.4	5.3	4.6	3.9
ROE	0.0	0.0	0.0	10.7	18.0	28.1	20.0	13.5
Cost to income	53.4	57.1	47.4	49.1	51.1	66.0	59.5	56.4
Asset quality ratios (%)								
GNPA	11.4	9.2	4.4	3.9	4.1	3.2	2.9	2.8
ECL	5.5	5.5	4.1	3.5	3.2	2.0	1.6	1.6

Source: Company, Centrum Research estimates

P&L (Rs mn)	FY17	FY18	FY19	FY20E	FY21E
Interest income	7,357	9,573	11,795	14,174	17,672
Interest expense	4,351	5,317	6,390	7,543	9,336
NII	3,005	4,256	5,405	6,631	8,336
Other income	410	194	1,935	2,063	2,489
Total income	3,415	4,450	7,340	8,694	10,825
Operating expenses	2,538	2,740	3,763	4,538	5,618
Employee	1,568	1,892	2,648	3,203	4,016
Others	914	708	1,002	1,206	1,459
PPOP	877	1,711	3,577	4,157	5,207
Provisions	505	445	521	774	973
PBT	372	1,266	3,056	3,383	4,234
Tax	127	445	1,107	1,218	1,524
PAT	245	821	1,949	2,165	2,710

Ratios	FY17	FY18	FY19	FY20E	FY21E
Growth (%)					
AUM	10.6	40.6	25.3	24.7	26.4
Borrowings	41.8	14.0	9.2	19.2	24.5
NII	32.5	41.6	27.0	22.7	25.7
Other income	(1.9)	(52.6)	895.9	6.6	20.7
Орех	58.3	7.9	37.4	20.6	23.8
PPoP	(19.0)	95.1	109.1	16.2	25.3
Provisions	142.7	(12.0)	17.1	48.6	25.7
PAT	(57.7)	235.3	137.3	11.1	25.2
Profitability (%)					
Yield on advances	17.4	18.1	17.6	17.0	16.9
Cost of funds	13.3	13.0	14.0	14.5	14.7
Spread	4.1	5.1	3.6	2.5	2.2
NIM (on AuM)	7.1	8.1	8.1	7.9	8.0
Other Income/ Total Income	12.0	4.4	8.2	7.5	7.3
Other Income / Total Assets	1.0	0.4	0.9	0.9	0.9
Cost/Income	74.3	61.6	51.3	52.2	51.9
Opex/ Avg AuM	6.3	5.0	5.8	6.2	6.4
Provisions	1.5	1.0	1.0	1.2	1.2
Tax Rate	34.1	35.1	36.2	36.0	36.0
RoA	0.6	1.5	3.0	3.0	3.1
RoE	6.3	12.2	19.1	18.0	18.9

DuPont (% avg assets)	FY17	FY18	FY19	FY20E	FY21E
Interest income	18.4	17.4	18.2	19.5	20.1
Interest expense	10.9	9.7	9.9	10.4	10.6
NII	7.5	7.7	8.3	9.1	9.5
Other income	1.0	0.4	3.0	2.8	2.8
Total income	8.5	8.1	11.3	12.0	12.3
Operating expenses	6.3	5.0	5.8	6.2	6.4
PPOP	2.2	3.1	5.5	5.7	5.9
Provisions	1.3	0.8	0.8	1.1	1.1
PBT	0.9	2.3	4.7	4.7	4.8
Tax	0.3	0.8	1.7	1.7	1.7
PAT	0.6	1.5	3.0	3.0	3.1

Source: Company, Centrum Research estimates

Dalama Chara (Dama)	EV4.7	E)/40	EV4.0	EVOCE	EV245
Balance Sheet (Rs mn)	FY17	FY18	FY19	FY20E	FY21E
Financial assets	45,514	61,096	66,082	77,026	96,361
Cash Bank balance	6,530	4,458	10,039	12,241	13,575
Loans	6,229	6,374	6,940 44,601	7,874 48,659	9,955
Investment	31,836 703	48,452		7,874	62,421
Other financial assets	216	1,486 326	4,219 284	377	9,955
Non-financial assets	1,773	1,530	992	1,181	1,493
Deferred tax assets	1,197	887	312	430	633
Fixed Assets	343	360	430	644	679
Other Non-fin. assets	233	283	250	107	181
Total Assets	47,287	62,626	67,073	78,208	97,854
Financial liabilities	42,633	53,436	55,230	65,378	81,351
Debt securities	5,881	9,193	9,759	11,636	14,484
Borrowings	32,233	38,624	37,200	44,355	55,212
Subordinated Debt	2,930	3,692	5,392	6,429	8,003
Other financial liabilities	1,589	1,927	2,879	2,958	3,653
Non-financial liabilities	145	270	329	321	401
Current tax liabilities	0	91	118	115	144
Provisions	92	102	135	132	165
Other Non-fin liabilities	53	77	76	74	93
Total equity	4,509	8,919	11,514	12,509	16,102
Share capital	371	473	485	485	535
Other equity	4,138	8,446	11,029	12,023	15,567
Total Liabilities	47,287	62,626	67,073	78,208	97,854
Balance Sheet ratios (%)					
Debt / Equity	9.1	5.8	4.5	5.0	4.8
Assets / Equity	10.5	7.0	5.8	6.3	6.1
Cash / Borrowings	0.3	0.2	0.3	0.3	0.3
Capital Adequacy (%)					
CRAR	24.1	21.2	28.5	29.4	30.3
Tier-1	16.6	14.6	19.9	20.6	21.2
Tier-2	7.6	6.6	8.6	8.8	9.1
Asset quality (%)					
GNPA (Rs mn)	218	2,152	1,779	2,469	3,334
NNPA (Rs mn)	218 80	2,152 742	1,779 1,061	2,469 1,382	3,334 1,728
		*		*	
NNPA (Rs mn)	80	742	1,061	1,382	1,728
NNPA (Rs mn) GNPA	80 0.6	742 4.2	1,061	1,382 3.1	1,728 3.3
NNPA (Rs mn) GNPA NNPA	80 0.6 0.2	742 4.2 1.5	1,061 2.8 1.7	1,382 3.1 1.7	1,728 3.3 1.7
NNPA (Rs mn) GNPA NNPA PCR	80 0.6 0.2 63.5	742 4.2 1.5 65.5	1,061 2.8 1.7 40.4	1,382 3.1 1.7 44.0	1,728 3.3 1.7 48.2
NNPA (Rs mn) GNPA NNPA PCR NNPA / Equity	80 0.6 0.2 63.5	742 4.2 1.5 65.5	1,061 2.8 1.7 40.4	1,382 3.1 1.7 44.0	1,728 3.3 1.7 48.2
NNPA (Rs mn) GNPA NNPA PCR NNPA / Equity Per share (Rs)	80 0.6 0.2 63.5 1.8	742 4.2 1.5 65.5 8.3	1,061 2.8 1.7 40.4 9.2	1,382 3.1 1.7 44.0 11.0	1,728 3.3 1.7 48.2 10.7
NNPA (Rs mn) GNPA NNPA PCR NNPA / Equity Per share (Rs) EPS	80 0.6 0.2 63.5 1.8	742 4.2 1.5 65.5 8.3	1,061 2.8 1.7 40.4 9.2	1,382 3.1 1.7 44.0 11.0	1,728 3.3 1.7 48.2 10.7
NNPA (Rs mn) GNPA NNPA PCR NNPA / Equity Per share (Rs) EPS BVPS	80 0.6 0.2 63.5 1.8 6.6	742 4.2 1.5 65.5 8.3 17.4 188.7	1,061 2.8 1.7 40.4 9.2 40.2 237.3	1,382 3.1 1.7 44.0 11.0 44.6 257.7	1,728 3.3 1.7 48.2 10.7 50.7 301.1
NNPA (Rs mn) GNPA NNPA PCR NNPA / Equity Per share (Rs) EPS BVPS ABVPS	80 0.6 0.2 63.5 1.8 6.6	742 4.2 1.5 65.5 8.3 17.4 188.7	1,061 2.8 1.7 40.4 9.2 40.2 237.3	1,382 3.1 1.7 44.0 11.0 44.6 257.7	1,728 3.3 1.7 48.2 10.7 50.7 301.1
NNPA (Rs mn) GNPA NNPA PCR NNPA / Equity Per share (Rs) EPS BVPS ABVPS Valuation (x)	80 0.6 0.2 63.5 1.8 6.6 121.4	742 4.2 1.5 65.5 8.3 17.4 188.7 173.0	1,061 2.8 1.7 40.4 9.2 40.2 237.3 215.4	1,382 3.1 1.7 44.0 11.0 44.6 257.7 229.3	1,728 3.3 1.7 48.2 10.7 50.7 301.1 268.8

P/ABV 3.7
Source: Company, Centrum Research estimates

#### Disclaimer

Centrum Broking Limited ("Centrum") is a full-service, Stock Broking Company and a member of The Stock Exchange, Mumbai (BSE) and National Stock Exchange of India Ltd. (NSE). Our holding company, Centrum Capital Ltd, is an investment banker and an underwriter of securities. As a group Centrum has Investment Banking, Advisory and other business relationships with a significant percentage of the companies covered by our Research Group. Our research professionals provide important inputs into the Group's Investment Banking and other business selection processes.

Recipients of this report should assume that our Group is seeking or may seek or will seek Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/report. Our Company and Group companies and their officers, directors and employees, including the analysts and others involved in the preparation or issuance of this material and their dependants, may on the date of this report or from, time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. Centrum or its affiliates do not own 1% or more in the equity of this company Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with recommendations/ information inconsistent or different those made in this report. In reviewing this document, you should be aware that any or all of the foregoing, among other things, may give rise to or potential conflicts of interest. We and our Group may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of Centrum. Centrum or its affiliates do not make a market in the security of the company for which this report or any report was written. Further, Centrum or its affiliates did not make a market in the subject company's securities at the time that the research report was published.

This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients of Centrum. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. Centrum will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Persons who may receive this document should consider and independently evaluate whether it is suitable for his/ her/their particular circumstances and, if necessary, seek professional/financial advice. Any such person shall be responsible for conducting his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document.

The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by or on behalf of the Company, Centrum, the authors of this report or any other person that these projections or forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts.

The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Centrum does not provide tax advice to its clients, and all investors are strongly advised to consult regarding any potential investment. Centrum and its affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. Certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities give rise to substantial risk and are not suitable for all investors. Please ensure that you have read and understood the current risk disclosure documents before entering into any derivative transactions.

This report/document has been prepared by Centrum, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. Centrum has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change.

This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of Centrum. This report or any portion hereof may not be printed, sold or distributed without the written consent of Centrum.

The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither Centrum nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. By accepting this report, you agree to be bound by the fore going limitations. No representation is made that this report is accurate or complete.

The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of Centrum Broking and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection.

Centrum Institutional Research 6

This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

Centrum and its affiliates have not managed or co-managed a public offering for the subject company in the preceding twelve months. Centrum and affiliates have not received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for service in respect of public offerings, corporate finance, debt restructuring, investment banking or other advisory services in a merger/acquisition or some other sort of specific transaction.

As per the declarations given by them, Mr. Gaurav Jani, Mr. Cyrus Dadabhoy & Mr. Rahul Nandwani, research analyst and and/or any of their family members do not serve as an officer, director or any way connected to the company/companies mentioned in this report. Further, as declared by them, they are not received any compensation from the above companies in the preceding twelve months. They do not hold any shares by them or through their relatives or in case if holds the shares then will not to do any transactions in the said scrip for 30 days from the date of release such report. Our entire research professionals are our employees and are paid a salary. They do not have any other material conflict of interest of the research analyst or member of which the research analyst knows of has reason to know at the time of publication of the research report or at the time of the public appearance.

While we would endeavour to update the information herein on a reasonable basis, Centrum, its associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Centrum from doing so.

Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Centrum policies, in circumstances where Centrum is acting in an advisory capacity to this company, or any certain other circumstances. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Centrum Broking Limited or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.

#### **Ratings definitions**

Our ratings denote the following 12-month forecast returns:

Buy - The stock is expected to return above 15%.

Add – The stock is expected to return 5-15%.

Reduce – The stock is expected to deliver -5-+5% returns.

Sell – The stock is expected to deliver <-5% returns.

#### Satin Creditcare



Source: Bloomberg

		Disclosure of Interest Statement	
1	Business activities of Centrum Broking Limited (CBL)	Centrum Broking Limited (hereinafter referred to as "CBL") is a registered member of NSE (Cash, F&O and Segments), MCX-SX (Currency Derivatives Segment) and BSE (Cash segment), Depository Participant of CDSL Portfolio Manager.	
2	Details of Disciplinary History of CBL	CBL has not been debarred/ suspended by SEBI or any other regulatory authority from accessing /dealing in sec	urities market.
3	Registration status of CBL:	CBL is registered with SEBI as a Research Analyst (SEBI Registration No. INH000001469)	
			Satin Creditcare
4	Whether Research analyst's or relatives'	have any financial interest in the subject company and nature of such financial interest	No
5	Whether Research analyst or relatives ha immediately preceding the date of public	eve actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month cation of the document.	No
6	Whether the research analyst or his relati	ives has any other material conflict of interest	No
7	Whether research analyst has received which such compensation is received	any compensation from the subject company in the past 12 months and nature of products / services for	No
8	Whether the Research Analyst has receive research report	ved any compensation or any other benefits from the subject company or third party in connection with the	No
9	Whether Research Analysts has served as	s an officer, director or employee of the subject company	No
10	Whether the Research Analyst has been e	engaged in market making activity of the subject company.	No
11	Whether it or its associates have manage	d or co-managed public offering of securities for the subject company in the past twelve months;	No
12	Whether it or its associates have receiv company in the past twelve months;	ed any compensation for investment banking or merchant banking or brokerage services from the subject	No
13	Whether it or its associates have received services from the subject company in the	d any compensation for products or services other than investment banking or merchant banking or brokerage past twelve months;	No

## Member (NSE and BSE). Member MSEI (Inactive)

Single SEBI Regn No.: INZ000205331

## **Depository Participant (DP)**

CDSL DP ID: 120 – 12200 SEBI REGD NO. : CDSL : IN-DP-CDSL-661-2012

PORTFOLIO MANAGER

SEBI REGN NO.: INP000004383

Research Analyst SEBI Registration No. INH000001469

> Mutual Fund Distributor AMFI REGN No. ARN- 147569

Website: www.centrum.co.in Investor Grievance Email ID: investor.grievances@centrum.co.in

## Compliance Officer Details:

Ashok D Kadambi (022) 4215 9937; Email ID: compliance@centrum.co.in

## Centrum Broking Ltd. (CIN: U67120MH1994PLC078125)

Registered Office Address Bombay Mutual Building, 2nd Floor, Dr. D. N. Road, Fort, Mumbai - 400 001

## **Corporate Office & Correspondence Address**

Centrum House 6th Floor, CST Road, Near Vidya Nagari Marg, Kalina, Santacruz (E), Mumbai 400 098.

Tel: (022) 4215 9000 Fax: +91 22 4215 9344